rolofylline has been researched along with Heart Failure in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (22.50) | 29.6817 |
| 2010's | 31 (77.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloomfield, DM; Cleland, JGF; Cotter, G; Davison, B; Dittrich, HC; Givertz, MM; Hillege, HL; Liu, LCY; Metra, M; O'Connor, CM; Ponikowski, P; Postmus, D; Teerlink, JR; Valente, MAE; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Cursack, GC; Davison, BA; Dittrich, HC; Edwards, C; Givertz, MM; Metra, M; Milo, O; O'Connor, CM; Ponikowski, P; Senger, S; Teerlink, JR; Voors, AA | 1 |
| Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Dimarco, JP; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Krishnamani, R; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA | 1 |
| Chiswell, K; Cleland, JG; Cotter, G; Davison, BA; Fiuzat, M; Givertz, MM; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Stevens, S; Teerlink, JR; Voors, AA | 1 |
| Cleland, JG; Cotter, G; Davison, BA; Dittrich, HC; Givertz, MM; Hillege, HL; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Postmus, D; Teerlink, JR; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Chiswell, K; Cleland, JG; Cotter, G; Davison, BA; Fiuzat, M; Givertz, MM; Grinfeld, L; Lotan, C; Mareev, V; Massie, BM; Mentz, RJ; Metra, M; O'Connor, CM; Ponikowski, P; Ruda, M; Stevens, SR; Teerlink, JR; Voors, AA | 1 |
| Gheorghiade, M; Pitt, B | 1 |
| Bloomfield, DM; Chiswell, K; Cleland, JG; Cotter, G; Davison, BA; Dittrich, HC; Fiuzat, M; Givertz, MM; Lazzarini, V; Mansoor, GA; Massie, BM; Mentz, RJ; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA | 1 |
| Cleland, JGF; Cotter, G; Davison, BA; Dittrich, HC; Edwards, C; Filippatos, G; Givertz, MM; Greenberg, B; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA | 1 |
| Berezikov, E; Bloomfield, DM; Bruno, N; Cleland, JG; Cotter, G; Davison, B; de Boer, RA; Dittrich, HC; Givertz, MM; Hillege, HL; Metra, M; O'Connor, CM; Ovchinnikova, ES; Pinto, YM; Ponikowski, P; Schmitter, D; Teerlink, JR; ter Maaten, JM; Valente, MA; van der Harst, P; van der Meer, P; van Veldhuisen, DJ; Vegter, EL; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Davison, BA; Dittrich, HC; Edwards, C; Givertz, MM; Massie, BM; Metra, M; Milo, O; O'Connor, CM; Ponikowski, P; Senger, S; Teerlink, JR; Voors, AA | 1 |
| Biegus, J; Bloomfield, DM; Cleland, JG; Cotter, G; Davison, BA; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Postmus, D; Teerlink, JR; Valente, MA; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Gheorghiade, M; Givertz, MM; Hillege, HL; Metra, M; O'Connor, CM; Ponikowski, P; Subacius, H; Teerlink, JR; Ter Maaten, JM; Valente, MA; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Davison, B; Dittrich, HC; Givertz, MM; Hillege, HL; Mentz, RJ; Metra, M; Meyer, S; O'Connor, CM; Ponikowski, P; Teerlink, JR; Tromp, J; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Givertz, MM; Hanberg, JS; Hillege, HL; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Ter Maaten, JM; Testani, JM; van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Davison, BA; Demissei, BG; Dittrich, HC; Edwards, C; Givertz, MM; Hillege, HL; Liu, LCY; Metra, M; O'Connor, CM; Ponikowski, P; Postmus, D; Teerlink, JR; Voors, AA | 1 |
| Berezikov, E; Bloomfield, D; Cleland, JG; Cotter, G; Davison, BA; Givertz, MM; Hagemeijer, Y; Khan, MA; Metra, M; O'Connor, CM; Ovchinnikova, ES; Ponikowski, P; Schmitter, D; Teerlink, JR; van der Harst, P; van der Meer, P; van Veldhuisen, DJ; Vegter, EL; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Givertz, MM; Matsue, Y; Metra, M; O'Connor, CM; Ponikowski, P; Struck, J; Teerlink, JR; Ter Maaten, JM; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Givertz, MM; Hillege, HL; Jaarsma, T; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Ter Maaten, JM; Tromp, J; van der Meer, P; van der Wal, MH; van Veldhuisen, DJ; Voors, AA | 1 |
| Gottlieb, SS | 1 |
| Bloomfield, DM; Cotter, G; Dittrich, HC; Massie, BM; Metra, M; O'Connor, CM; Weatherley, BD | 1 |
| Dohadwala, MM; Givertz, MM | 1 |
| Givertz, MM; Slawsky, MT | 1 |
| Bloomfield, DM; Cotter, G; Dittrich, HC; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Weatherley, BD | 1 |
| Bloomfield, DM; Cotter, G; DeLucca, P; Dittrich, HC; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Weatherley, BD | 1 |
| Cleland, JG; Cotter, G; Dittrich, HC; Givertz, MM; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA; Weatherley, BD | 1 |
| Chen, E; Cotter, G; Dittrich, H; Fujita, KP; Givertz, MM; Massie, BM; Metra, M; Mitrovic, V; Murray, M; O'Connor, CM; Ponikowski, P; Weatherley, BD | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; DeLucca, P; Dittrich, HC; Givertz, MM; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Salerno, CM; Teerlink, JR; Voors, A; Weatherley, BD | 1 |
| Gheorghiade, M; Ruschitzka, F | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Davison, BA; DeLucca, P; Dittrich, H; Givertz, MM; Jia, G; Mansoor, GA; Massie, B; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA | 1 |
| Cleland, JG; Cotter, G; DeLucca, P; Dittrich, HC; Givertz, MM; Mansoor, GA; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA; Weatherley, BD | 1 |
| Bloomfield, D; Cleland, J; Cotter, G; Davison, BA; Delucca, P; Dittrich, HC; Fiuzat, M; Fujita, K; Givertz, MM; Jia, G; Lombardi, C; Mansoor, G; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Voors, AA | 1 |
| Carson, PE; Cleland, JG; Cotter, G; Davison, BA; Delucca, P; Dittrich, H; Givertz, MM; Hauptman, PJ; Iragui, VJ; Lovett, DH; Mansoor, GA; Massie, BM; Metra, M; Miller, AB; Mohr, JP; O'Connor, CM; Piña, IL; Ponikowski, P; Salerno, CM; Teerlink, JR; Thomson, S; Varosy, PD; Voors, AA; Wolko, D; Zile, MR | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Loh, PH; Tin, L | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Hobson, N; Witte, KK | 1 |
| Callahan, J; Dittrich, HC; Dowling, T; Gupta, DK; Hack, TC; Thomson, S | 1 |
| Dittrich, HC; Fields, TK; Givertz, MM; Massie, BM; Pearson, LL | 1 |
5 review(s) available for rolofylline and Heart Failure
| Article | Year |
|---|---|
Acute decompensated heart failure: update on new and emerging evidence and directions for future research.
Topics: Adrenomedullin; Atrial Natriuretic Factor; Biomarkers; Blood Pressure Monitoring, Ambulatory; Cardiotonic Agents; Clinical Trials as Topic; Diet, Sodium-Restricted; Diuretics; Dopamine; Dose-Response Relationship, Drug; Dyspnea; Glycopeptides; Heart Failure; Hemofiltration; Hospitalization; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Peptide Fragments; Prognosis; Protein Precursors; Quality of Health Care; Relaxin; Risk Assessment; Saline Solution, Hypertonic; Urea; Vasodilator Agents; Xanthines | 2013 |
Adenosine A1 antagonists and the cardiorenal syndrome.
Topics: Adenosine A1 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Kidney Function Tests; Male; Mice; Prognosis; Randomized Controlled Trials as Topic; Receptor, Adenosine A1; Risk Assessment; Severity of Illness Index; Syndrome; Treatment Outcome; Xanthines | 2008 |
Role of adenosine antagonism in the cardiorenal syndrome.
Topics: Adenosine A1 Receptor Antagonists; Animals; Heart Failure; Hospital Mortality; Humans; Kidney Failure, Chronic; Registries; Syndrome; Xanthines | 2008 |
Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure.
Topics: Adenosine A1 Receptor Antagonists; Animals; Cardiovascular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Renal Insufficiency, Chronic; Syndrome; Xanthines | 2009 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
26 trial(s) available for rolofylline and Heart Failure
| Article | Year |
|---|---|
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.
Topics: Acute Disease; Aged; Biomarkers; Diuretics; Female; Heart Failure; Humans; Male; Xanthines | 2017 |
Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized W
Topics: Aged; Blood Pressure; Creatinine; Diagnostic Tests, Routine; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Patient Discharge; Patient Readmission; Predictive Value of Tests; Purinergic P1 Receptor Antagonists; Serum Albumin; Sodium; Survival Rate; Treatment Outcome; Urea; Xanthines | 2014 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Patient Readmission; Renal Insufficiency; Sulfonamides; Torsemide; Treatment Outcome; Weight Loss; Xanthines | 2014 |
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Aged, 80 and over; Diuretics; Europe, Eastern; Female; Geography; Heart Failure; Hospitalization; Humans; Internationality; Length of Stay; Male; Middle Aged; Quality of Life; Russia; Xanthines | 2014 |
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Blood Pressure; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Severity of Illness Index; Sodium; Treatment Outcome; Xanthines | 2015 |
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
Topics: Acute Disease; Disease Progression; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Prognosis; Relaxin; Treatment Outcome; Xanthines | 2015 |
MicroRNAs relate to early worsening of renal function in patients with acute heart failure.
Topics: Acute Disease; Aged; Biomarkers; Creatinine; Disease Progression; Diuretics; Double-Blind Method; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gene Expression Regulation; Glomerular Filtration Rate; Heart Failure; Humans; Male; MicroRNAs; Real-Time Polymerase Chain Reaction; Renal Insufficiency; Retrospective Studies; Xanthines | 2016 |
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Decision Support Techniques; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Patient Readmission; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2016 |
Acute heart failure in the young: Clinical characteristics and biomarker profiles.
Topics: Acute Disease; Biomarkers; Comorbidity; Diuretics; Female; Heart Failure; Hospitalization; Humans; Kidney Function Tests; Long Term Adverse Effects; Male; Medication Therapy Management; Middle Aged; Outcome and Process Assessment, Health Care; Severity of Illness Index; Stroke Volume; Symptom Assessment; Xanthines | 2016 |
Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Chlorides; Disease Progression; Diuretics; Down-Regulation; Drug Resistance; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Xanthines | 2016 |
Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Acuity; Protective Agents; Reproducibility of Results; Risk Assessment; Treatment Outcome; Xanthines | 2016 |
Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Databases, Factual; Diuretics; Female; Heart Failure; Hospitalization; Humans; Male; MicroRNAs; Middle Aged; Xanthines | 2016 |
Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure.
Topics: Acute Disease; Biomarkers; Enkephalins; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein Precursors; Xanthines | 2017 |
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).
Topics: Acute Disease; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Diuretics; Female; Heart Failure; Hospitalization; Humans; Kidney; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Reproducibility of Results; Treatment Outcome; Xanthines | 2017 |
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Cardiovascular Agents; Confidence Intervals; Disease Progression; Diuresis; Dyspnea; Female; Heart Failure; Humans; Male; Pilot Projects; Renal Insufficiency; Risk; Risk Factors; Xanthines | 2008 |
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect
Topics: Adenosine A1 Receptor Antagonists; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Kidney Function Tests; Male; Pilot Projects; Receptor, Adenosine A1; Stroke Volume; Treatment Outcome; Xanthines | 2010 |
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study.
Topics: Aged; Diuretics; Dyspnea; Europe; Female; Health Status Indicators; Heart Failure; Hospitalization; Humans; Italy; Length of Stay; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Treatment Outcome; Xanthines | 2010 |
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.
Topics: Aged; Diuretics; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Kidney Function Tests; Least-Squares Analysis; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Sodium Potassium Chloride Symporter Inhibitors; Xanthines | 2010 |
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Odds Ratio; Patient Readmission; Proportional Hazards Models; Risk; Treatment Failure; Xanthines | 2010 |
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Dyspnea; Female; Heart Failure; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Prospective Studies; Treatment Outcome; Xanthines | 2011 |
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylli
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Kidney; Kidney Diseases; Male; Pilot Projects; Stroke Volume; Treatment Outcome; Xanthines | 2011 |
Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
Topics: Acute Disease; Aged; Biomarkers; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardium; Pilot Projects; Predictive Value of Tests; Prognosis; Purinergic P1 Receptor Antagonists; Time Factors; Treatment Outcome; Troponin; Xanthines | 2011 |
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Aged, 80 and over; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Renal Insufficiency; Risk Factors; Stroke; Time Factors; Xanthines | 2012 |
Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF.
Topics: Arrhythmias, Cardiac; Canrenone; Cardiac Pacing, Artificial; Defibrillators, Implantable; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Risk Assessment; Xanthines | 2007 |
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Topics: Adenosine A1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Ambulatory Care; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Receptor, Adenosine A1; Renal Plasma Flow; Xanthines | 2007 |
The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Topics: Aged; Creatinine; Diuresis; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Renal Insufficiency; Sodium; Treatment Outcome; Xanthines | 2007 |
9 other study(ies) available for rolofylline and Heart Failure
| Article | Year |
|---|---|
Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.
Topics: Acute Disease; Aged; Aged, 80 and over; Creatinine; Female; Heart Failure; Hospitalization; Humans; Kidney; Male; Middle Aged; Patient Readmission; Prognosis; Proportional Hazards Models; Xanthines | 2018 |
Renal function trajectories and clinical outcomes in acute heart failure.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Urea Nitrogen; Comorbidity; Creatinine; Female; Follow-Up Studies; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Multivariate Analysis; Predictive Value of Tests; Purinergic P1 Receptor Antagonists; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Xanthines | 2014 |
Geographic variation in heart failure trials: time for scepticism?
Topics: Diuretics; Female; Heart Failure; Hospitalization; Humans; Length of Stay; Male; Xanthines | 2014 |
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality.
Topics: Acute Disease; Aged; Comorbidity; Diabetes Mellitus; Disease Progression; Diuretics; Edema; Female; Heart Failure; Hospitalization; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Ischemia; Odds Ratio; Patient Readmission; Proportional Hazards Models; Randomized Controlled Trials as Topic; Renal Insufficiency; Severity of Illness Index; Xanthines | 2016 |
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
Topics: Acute Disease; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Disease Progression; Diuretics; Female; Heart Failure; Humans; Liver Function Tests; Male; Middle Aged; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Serum Albumin; Xanthines | 2016 |
Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Prognosis; Renal Insufficiency; Severity of Illness Index; Sodium Potassium Chloride Symporter Inhibitors; Xanthines | 2010 |
HOTLINE III: End of the line for rolofylline?
Topics: Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Reproducibility of Results; Xanthines | 2009 |
Beyond dyspnoea as an endpoint in acute heart failure trials.
Topics: Adenosine A1 Receptor Antagonists; Dyspnea; Female; Heart Failure; Humans; Male; Xanthines | 2011 |
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.
Topics: Anemia; Atorvastatin; Cardiology; Clinical Trials as Topic; Congresses as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Europe; Exercise Tolerance; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Societies, Medical; Xanthines | 2006 |